Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: The COMPLETE study

Zohar Yehoshua, Carlos Alexandre De Amorim Garcia Filho, Renata Portella Nunes, Giovanni Gregori, Fernando M. Penha, Andrew A. Moshfeghi, Kang Zhang, Srinivas Sadda, William J Feuer, Philip J Rosenfeld

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Purpose To evaluate the effect of eculizumab, a systemic inhibitor of complement component (C5), on the growth of geographic atrophy (GA) in patients with age-related macular degeneration (AMD). Design Prospective, double-masked, randomized clinical trial. Participants Patients with GA measuring from 1.25 to 18 mm2 based on spectral-domain optical coherence tomography imaging. Methods Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 6 months. In the eculizumab treatment arm, the first 10 patients received a low-dose regimen of 600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24, and the next 10 patients received a high-dose regimen of 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24. The placebo group was infused with saline. Patients were observed off treatment for an additional 26 weeks. Both normal-luminance and low-luminance visual acuities were measured throughout the study, and the low-luminance deficits were calculated as the difference between the letter scores. Main Outcome Measures Change in area of GA at 26 weeks. Results Thirty eyes of 30 patients were enrolled. Eighteen fellow eyes also met inclusion criteria and were analyzed as a secondary endpoint. For the 30 study eyes, mean square root of GA area measurements ± standard deviation at baseline were 2.55±0.94 and 2.02±0.74 mm in the eculizumab and placebo groups, respectively (P = 0.13). At 26 weeks, GA enlarged by a mean of 0.19±0.12 and 0.18±0.15 mm in the eculizumab and placebo groups, respectively (P = 0.96). At 52 weeks of follow-up, GA enlarged by a mean of 0.37±0.22 mm in the eculizumab-treated eyes and by a mean of 0.37±0.21 mm in the placebo group (P = 0.93, 2 sample t test). None of the eyes converted to wet AMD. No drug-related adverse events were identified. Conclusions Systemic complement inhibition with eculizumab was well tolerated through 6 months but did not decrease the growth rate of GA significantly. However, there was a statistically significant correlation between the low-luminance deficit at baseline and the progression of GA over 6 months.

Original languageEnglish
Pages (from-to)693-701
Number of pages9
JournalOphthalmology
Volume121
Issue number3
DOIs
StatePublished - Mar 1 2014

Fingerprint

Geographic Atrophy
Macular Degeneration
Placebos
Complement C5
Inhibition (Psychology)
eculizumab
Optical Coherence Tomography
Growth
Drug-Related Side Effects and Adverse Reactions
Visual Acuity
Arm
Randomized Controlled Trials
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration : The COMPLETE study. / Yehoshua, Zohar; Alexandre De Amorim Garcia Filho, Carlos; Nunes, Renata Portella; Gregori, Giovanni; Penha, Fernando M.; Moshfeghi, Andrew A.; Zhang, Kang; Sadda, Srinivas; Feuer, William J; Rosenfeld, Philip J.

In: Ophthalmology, Vol. 121, No. 3, 01.03.2014, p. 693-701.

Research output: Contribution to journalArticle

Yehoshua, Z, Alexandre De Amorim Garcia Filho, C, Nunes, RP, Gregori, G, Penha, FM, Moshfeghi, AA, Zhang, K, Sadda, S, Feuer, WJ & Rosenfeld, PJ 2014, 'Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: The COMPLETE study', Ophthalmology, vol. 121, no. 3, pp. 693-701. https://doi.org/10.1016/j.ophtha.2013.09.044
Yehoshua, Zohar ; Alexandre De Amorim Garcia Filho, Carlos ; Nunes, Renata Portella ; Gregori, Giovanni ; Penha, Fernando M. ; Moshfeghi, Andrew A. ; Zhang, Kang ; Sadda, Srinivas ; Feuer, William J ; Rosenfeld, Philip J. / Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration : The COMPLETE study. In: Ophthalmology. 2014 ; Vol. 121, No. 3. pp. 693-701.
@article{b971ce3e453b42faa9a883fd63ebe919,
title = "Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: The COMPLETE study",
abstract = "Purpose To evaluate the effect of eculizumab, a systemic inhibitor of complement component (C5), on the growth of geographic atrophy (GA) in patients with age-related macular degeneration (AMD). Design Prospective, double-masked, randomized clinical trial. Participants Patients with GA measuring from 1.25 to 18 mm2 based on spectral-domain optical coherence tomography imaging. Methods Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 6 months. In the eculizumab treatment arm, the first 10 patients received a low-dose regimen of 600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24, and the next 10 patients received a high-dose regimen of 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24. The placebo group was infused with saline. Patients were observed off treatment for an additional 26 weeks. Both normal-luminance and low-luminance visual acuities were measured throughout the study, and the low-luminance deficits were calculated as the difference between the letter scores. Main Outcome Measures Change in area of GA at 26 weeks. Results Thirty eyes of 30 patients were enrolled. Eighteen fellow eyes also met inclusion criteria and were analyzed as a secondary endpoint. For the 30 study eyes, mean square root of GA area measurements ± standard deviation at baseline were 2.55±0.94 and 2.02±0.74 mm in the eculizumab and placebo groups, respectively (P = 0.13). At 26 weeks, GA enlarged by a mean of 0.19±0.12 and 0.18±0.15 mm in the eculizumab and placebo groups, respectively (P = 0.96). At 52 weeks of follow-up, GA enlarged by a mean of 0.37±0.22 mm in the eculizumab-treated eyes and by a mean of 0.37±0.21 mm in the placebo group (P = 0.93, 2 sample t test). None of the eyes converted to wet AMD. No drug-related adverse events were identified. Conclusions Systemic complement inhibition with eculizumab was well tolerated through 6 months but did not decrease the growth rate of GA significantly. However, there was a statistically significant correlation between the low-luminance deficit at baseline and the progression of GA over 6 months.",
author = "Zohar Yehoshua and {Alexandre De Amorim Garcia Filho}, Carlos and Nunes, {Renata Portella} and Giovanni Gregori and Penha, {Fernando M.} and Moshfeghi, {Andrew A.} and Kang Zhang and Srinivas Sadda and Feuer, {William J} and Rosenfeld, {Philip J}",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.ophtha.2013.09.044",
language = "English",
volume = "121",
pages = "693--701",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration

T2 - The COMPLETE study

AU - Yehoshua, Zohar

AU - Alexandre De Amorim Garcia Filho, Carlos

AU - Nunes, Renata Portella

AU - Gregori, Giovanni

AU - Penha, Fernando M.

AU - Moshfeghi, Andrew A.

AU - Zhang, Kang

AU - Sadda, Srinivas

AU - Feuer, William J

AU - Rosenfeld, Philip J

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Purpose To evaluate the effect of eculizumab, a systemic inhibitor of complement component (C5), on the growth of geographic atrophy (GA) in patients with age-related macular degeneration (AMD). Design Prospective, double-masked, randomized clinical trial. Participants Patients with GA measuring from 1.25 to 18 mm2 based on spectral-domain optical coherence tomography imaging. Methods Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 6 months. In the eculizumab treatment arm, the first 10 patients received a low-dose regimen of 600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24, and the next 10 patients received a high-dose regimen of 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24. The placebo group was infused with saline. Patients were observed off treatment for an additional 26 weeks. Both normal-luminance and low-luminance visual acuities were measured throughout the study, and the low-luminance deficits were calculated as the difference between the letter scores. Main Outcome Measures Change in area of GA at 26 weeks. Results Thirty eyes of 30 patients were enrolled. Eighteen fellow eyes also met inclusion criteria and were analyzed as a secondary endpoint. For the 30 study eyes, mean square root of GA area measurements ± standard deviation at baseline were 2.55±0.94 and 2.02±0.74 mm in the eculizumab and placebo groups, respectively (P = 0.13). At 26 weeks, GA enlarged by a mean of 0.19±0.12 and 0.18±0.15 mm in the eculizumab and placebo groups, respectively (P = 0.96). At 52 weeks of follow-up, GA enlarged by a mean of 0.37±0.22 mm in the eculizumab-treated eyes and by a mean of 0.37±0.21 mm in the placebo group (P = 0.93, 2 sample t test). None of the eyes converted to wet AMD. No drug-related adverse events were identified. Conclusions Systemic complement inhibition with eculizumab was well tolerated through 6 months but did not decrease the growth rate of GA significantly. However, there was a statistically significant correlation between the low-luminance deficit at baseline and the progression of GA over 6 months.

AB - Purpose To evaluate the effect of eculizumab, a systemic inhibitor of complement component (C5), on the growth of geographic atrophy (GA) in patients with age-related macular degeneration (AMD). Design Prospective, double-masked, randomized clinical trial. Participants Patients with GA measuring from 1.25 to 18 mm2 based on spectral-domain optical coherence tomography imaging. Methods Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 6 months. In the eculizumab treatment arm, the first 10 patients received a low-dose regimen of 600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24, and the next 10 patients received a high-dose regimen of 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24. The placebo group was infused with saline. Patients were observed off treatment for an additional 26 weeks. Both normal-luminance and low-luminance visual acuities were measured throughout the study, and the low-luminance deficits were calculated as the difference between the letter scores. Main Outcome Measures Change in area of GA at 26 weeks. Results Thirty eyes of 30 patients were enrolled. Eighteen fellow eyes also met inclusion criteria and were analyzed as a secondary endpoint. For the 30 study eyes, mean square root of GA area measurements ± standard deviation at baseline were 2.55±0.94 and 2.02±0.74 mm in the eculizumab and placebo groups, respectively (P = 0.13). At 26 weeks, GA enlarged by a mean of 0.19±0.12 and 0.18±0.15 mm in the eculizumab and placebo groups, respectively (P = 0.96). At 52 weeks of follow-up, GA enlarged by a mean of 0.37±0.22 mm in the eculizumab-treated eyes and by a mean of 0.37±0.21 mm in the placebo group (P = 0.93, 2 sample t test). None of the eyes converted to wet AMD. No drug-related adverse events were identified. Conclusions Systemic complement inhibition with eculizumab was well tolerated through 6 months but did not decrease the growth rate of GA significantly. However, there was a statistically significant correlation between the low-luminance deficit at baseline and the progression of GA over 6 months.

UR - http://www.scopus.com/inward/record.url?scp=84896695485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896695485&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2013.09.044

DO - 10.1016/j.ophtha.2013.09.044

M3 - Article

C2 - 24289920

AN - SCOPUS:84896695485

VL - 121

SP - 693

EP - 701

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 3

ER -